InVivo Therapeutics (NSDQ:NVIV) said today that the Toronto Western Hospital will be the 1st Canadian site in the newly-launched study of its neuro-spinal scaffold in patients with acute, complete AIS A cervical spinal cord injuries.
The neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting, InVivo said.
Dr. Michael Fehlings will serve as principal investigator at the site, the Cambridge, Mass.-based comapny said. Fehlings also serves as a principal investigator at the hospital for InVivo’s Inspire study of the neuro-spinal scaffold for treating patients with acute thoracic spinal cord injuries.
“Our centre remains enthusiastic about addressing the unmet need in cervical spinal cord injuries and being part of InVivo’s pioneering efforts in this exciting and promising field,” Dr. Fehlings said in a prepared statement.
“We are thrilled to launch our cervical study in Canada with one of the most prominent leaders in spinal cord injury research. We admire Dr. Fehlings’ and Toronto Western Hospital’s dedication to helping us evaluate our technology through both the cervical study and the INSPIRE study. We look forward to continuing to work with Dr. Fehlings and Toronto Western Hospital,” CEO Mark Perrin said in a press release.
Earlier this week, InVivo announced that a patient enrolled in January in its Inspire study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the 7th patient from the 11-patient group to have an AIS grade improvement with at least 1-month of follow-up.
2 other patients have not yet had their 1-month follow-up visit, according to the company. InVivo added that the AIS conversation rate observed in its Inspire study is “considerably higher” than the rates found in a range of spinal cord injury natural history databases.
The post InVivo enlists 1st Canadian site in cervical spinal scaffold study appeared first on MassDevice.
from MassDevice http://ift.tt/2nFgz7q
Cap comentari:
Publica un comentari a l'entrada